We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals

99 hedge funds and large institutions have $79.7M invested in Zentalis Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 33

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4.11% less ownership

Funds ownership: 77.28% → 73.17% (-4.1%)

15% less funds holding

Funds holding: 117 → 99 (-18)

28% less capital inflows, than outflows

Capital inflows: $10M | Capital outflows: $13.9M

42% less call options, than puts

Call options by funds: $65K | Put options by funds: $112K

78% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 23

Holders
99
Holders Change
-18
Holders Change %
-15.38%
% of All Funds
1.29%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
36
Reduced
33
Closed
23
Calls
$65​K
Puts
$112​K
Net Calls
-⁠$47​K
Net Calls Change
+$26​K

ZNTL Hedge Fund Activity: Q3 2025 in Review

99 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2025, worth a combined $79.7M — up 24% from $64.5M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of ZNTL and 5 opened new positions — a net loss of 18 holders — while 33 trimmed existing stakes and 36 added.

The largest buyer was Citadel Advisors, adding an estimated $2.42M. The largest seller was Millennium Management, cutting an estimated $3.86M.

  • 99 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2025, down from 117 in Q2 2025.
  • Funds reported $79.7M of Zentalis Pharmaceuticals stock for Q3 2025, up 24% quarter-over-quarter.
  • 5 funds opened new Zentalis Pharmaceuticals positions in Q3 2025 and 23 closed out, a net change of -18 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q3 2025 was Citadel Advisors, an estimated $2.42M added.
  • The largest Zentalis Pharmaceuticals seller in Q3 2025 was Millennium Management, an estimated $3.86M sold.

Based on aggregated 13F filings for Q3 2025.